5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | BUY | BUY | NEUTRAL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.55▲ | 2.60▼ | 2.59▼ | 2.33▲ | 2.54▲ |
MA10 | 2.56▼ | 2.59▼ | 2.55▲ | 2.46▲ | 2.22▲ |
MA20 | 2.59▼ | 2.56▼ | 2.51▲ | 2.72▼ | 2.38▲ |
MA50 | 2.60▼ | 2.42▲ | 2.35▲ | 2.27▲ | 5.52▼ |
MA100 | 2.56▼ | 2.37▲ | 2.53▲ | 2.51▲ | 7.26▼ |
MA200 | 2.51▲ | 2.57▼ | 2.51▲ | 4.74▼ | 9.12▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.007▼ | -0.010▼ | 0.004▲ | -0.054▼ | 0.275▲ |
RSI | 40.135▼ | 52.767▲ | 57.457▲ | 51.838▲ | 43.235▼ |
STOCH | 18.056▼ | 60.074 | 75.451 | 39.015 | 40.019 |
WILL %R | -76.471▼ | -43.750 | -35.593 | -43.478 | -66.134 |
CCI | -91.244 | -46.066 | 32.746 | 3.012 | 48.825 |
Wednesday, August 13, 2025 10:49 AM
Iovance Biotherapeutics (IOVA) announced revenue gains despite losses in its Q2 2025 results. On August 7, the company reiterated its product revenue guidance for 2025 within the $250 to $300 million ...
|
Friday, August 08, 2025 04:31 PM
Investors might have liked to see that statement bolstered by a guidance raise. However, Iovance stuck to its existing forecast of $250 million to $300 million anchored, of course, by Amtagvi. The ...
|
Friday, August 08, 2025 12:48 PM
Iovance Biotherapeutics (NASDAQ:IOVA) shares tanked after the company failed to meet top-line as well as bottom-line expectations. The company reported a quarterly revenue of $60M, missing estimate by ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 2.46 | 2.66 | 2.41 | 2.55 | 9,435,800 |
14/08/25 | 2.39 | 2.56 | 2.35 | 2.45 | 11,244,200 |
13/08/25 | 2.28 | 2.53 | 2.26 | 2.45 | 15,233,600 |
12/08/25 | 2.02 | 2.26 | 2.01 | 2.23 | 16,348,800 |
11/08/25 | 2.14 | 2.20 | 1.95 | 1.97 | 15,376,200 |
08/08/25 | 1.91 | 2.30 | 1.90 | 2.11 | 43,398,200 |
07/08/25 | 2.61 | 2.69 | 2.56 | 2.64 | 27,553,300 |
06/08/25 | 2.76 | 2.78 | 2.57 | 2.58 | 11,565,600 |
05/08/25 | 2.78 | 2.84 | 2.70 | 2.75 | 8,058,341 |
04/08/25 | 2.85 | 2.92 | 2.73 | 2.83 | 12,527,100 |
|
|
||||
|
|
||||
|
|